Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug combination/ 26489112 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken. |
| Name | Type | Description |
|---|---|---|
| Drug combination/ 26489112 | DRUG | On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken. |
Inclusion Criteria: * If a woman, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) before entr...
JNJ-26489112 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The only completed trial assessed its pharmacokinetics and drug interactions in healthy adults, indicating it is being evaluated for safety and how the body processes it.
JNJ-26489112 is being developed by Johnson & Johnson, traded on the New York Stock Exchange under the ticker JNJ. The company sponsored a Phase 1 study of the drug in healthy volunteers, which has been completed.
JNJ-26489112 is in Phase 1 clinical development. The single trial, NCT01147887, was a Phase 1 study that has been completed. The drug remains investigational and has not been approved by regulatory authorities.
JNJ-26489112 has one completed clinical trial, NCT01147887, titled "A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers." This Phase 1 study enrolled 20 healthy adults in Belgium and was not randomized, double-blind, or controlled.
JNJ-26489112 is not FDA approved. It is an investigational drug that has only been studied in a completed Phase 1 trial in healthy volunteers. No efficacy trials in patients have been conducted, and the drug remains in early clinical development.